FDA Grants Quick Review Psychedelic Drugs, First Approvals Could Come As Soon As Summer

The FDA has announced accelerated review pathways for psychedelic treatments targeting serious mental health conditions, following an executive order from President Trump directing agencies to expand access to emerging therapies.

FDA Commissioner Marty Makary said the medications "have the potential to address the nation's mental health crisis, including conditions like treatment resistant depression, alcoholism and other serious mental health and substance abuse conditions." Makary told NBC News that with the accelerated review, first approvals could come as early as this year.

The move represents a remarkable shift for an agency that has historically been cautious about psychedelic therapies. MDMA-assisted therapy for PTSD and psilocybin for treatment-resistant depression are the leading candidates for near-term approval, both of which have shown promising results in clinical trials.

The executive order and FDA's responsive action reflect a growing bipartisan recognition that existing treatments for severe mental health conditions are insufficient. Treatment-resistant depression affects roughly one-third of the 30 million Americans with depression, and current medications fail to produce adequate relief for many of those patients.

Critics caution that accelerated review shouldn't mean lowered standards. Previous psychedelic trials have faced criticism over methodological issues, including difficulty blinding participants to treatment conditions and concerns about the durability of therapeutic effects after the acute experience. The FDA's challenge will be maintaining rigorous evaluation while meeting the accelerated timeline.

The pharmaceutical industry has taken notice. Several companies developing psychedelic compounds have seen stock increases following the announcement, and venture capital interest in the sector, which had cooled after a hype cycle in 2021-2022, appears to be warming again.

**What This Means For You:** If you or someone you know has treatment-resistant depression or PTSD, FDA-approved psychedelic therapies could become available within 12-18 months — initially through controlled clinical settings, not self-medication. For investors, the psychedelic sector is entering a phase where regulatory clarity could separate viable companies from speculative ones. Watch for Phase 3 trial results from the leading candidates; those will determine which companies get the first approvals.